Healthcare provider profile · identity verified

Patrick John Contino, M.D.

Family Practice · ASHEVILLE, NC · NPI 1952393324

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	250	72
Lisinopril	Lisinopril	184	64
Amlodipine Besylate	Amlodipine Besylate	179	57
Metformin Hcl	Metformin Hcl	163	51
Gabapentin	Gabapentin	157	48
Jardiance	Empagliflozin	157	46
Omeprazole	Omeprazole	121	41
Trazodone Hcl	Trazodone Hcl	104	31
Ozempic	Semaglutide	99	23
Levothyroxine Sodium	Levothyroxine Sodium	88	22
Rosuvastatin Calcium	Rosuvastatin Calcium	86	30
Hydrochlorothiazide	Hydrochlorothiazide	85	26
Albuterol Sulfate Hfa	Albuterol Sulfate	84	27
Losartan Potassium	Losartan Potassium	80	35
Fluticasone Propionate	Fluticasone Propionate	79	21
Tamsulosin Hcl	Tamsulosin Hcl	75	19
Metoprolol Succinate	Metoprolol Succinate	58	19
Oxycodone Hcl	Oxycodone Hcl	56	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	55	19
Pantoprazole Sodium	Pantoprazole Sodium	55	16
Alprazolam	Alprazolam	54	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	53	15
Esomeprazole Magnesium	Esomeprazole Magnesium	50	suppressed
Furosemide	Furosemide	47	17
Meloxicam	Meloxicam	47	17
Duloxetine Hcl	Duloxetine Hcl	46	15
Spironolactone	Spironolactone	45	13
Montelukast Sodium	Montelukast Sodium	44	11
Metoprolol Tartrate	Metoprolol Tartrate	40	13
Tizanidine Hcl	Tizanidine Hcl	40	12
Eliquis	Apixaban	36	11
Simvastatin	Simvastatin	36	14
Metformin Hcl Er	Metformin Hcl	35	12
Trulicity	Dulaglutide	35	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	16
Mounjaro	Tirzepatide	33	suppressed
Paroxetine Hcl	Paroxetine Hcl	31	suppressed
Symbicort	Budesonide/Formoterol Fumarate	31	suppressed
Byetta	Exenatide	29	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Clonazepam	Clonazepam	27	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Valacyclovir	Valacyclovir Hcl	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	26	suppressed
Clozapine	Clozapine	26	suppressed
Prednisone	Prednisone	26	21
Baclofen	Baclofen	25	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Victoza 3-Pak	Liraglutide	23	13
Hydroxyzine Hcl	Hydroxyzine Hcl	22	12
Linzess	Linaclotide	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Potassium Chloride	Potassium Chloride	22	suppressed
Telmisartan	Telmisartan	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Lamotrigine	Lamotrigine	20	suppressed
Risperidone	Risperidone	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	15
Techlite Pen Needle	Pen Needle, Diabetic	19	13
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Omnipod 5 Dexg7g6 Pods (Gen 5)	Insulin Pump Cart,auto,bt,g6/7	17	suppressed
Prezcobix	Darunavir/Cobicistat	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Spiriva Handihaler	Tiotropium Bromide	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Topiramate	Topiramate	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Colchicine	Colchicine	14	suppressed
Humalog	Insulin Lispro	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Atenolol	Atenolol	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Naltrexone Hcl	Naltrexone Hcl	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Constulose	Lactulose	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Varenicline Tartrate	Varenicline Tartrate	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error